Effect of loratadine combined with montelukast sodium in the treatment of cough after upper respiratory tract infection in children
氯雷他定联合孟鲁司特钠治疗小儿上呼吸道感染后咳嗽的效果分析

摘要

目的 讨论氯雷他定联合孟鲁司特钠治疗小儿上呼吸道感染后咳嗽的效果。方法 选取该院2020年12月到2021年12月收治的上呼吸道感染后咳嗽患儿60例进行研究，随机分为两组，对照组30例，单用氯雷他定，观察组30例，予以孟鲁司特钠氯雷他定治疗。结果 观察组治疗7d后咳嗽、咯痰症状积分更低；临床有效率（93.33%）较对照组（76.67%）更高；IL-4、IgE、TNF－α等血清炎性因子水平较对照组更低；不良反应率仅为3.33%，远低于对照组的13.33%，2组相比，差异具有统计学意义（P<0.05）。结论 氯雷他定+孟鲁司特钠可将患儿咳嗽敏感性降至最小，促使气道高反应性得到有效改善，镇咳平喘、防范肺炎之效极佳，值得广为运用。

Abstract

Objective: To discuss the effect of loratadine combined with montelukast sodium in the treatment of cough after upper respiratory tract infection in children.
Methods: 60 children with cough after upper respiratory tract infection treated in our hospital from December 2020 to December 2021 were randomly divided into two groups. 30 cases in the control group were treated with loratadine alone and 30 cases in the observation group were treated with montelukast sodium loratadine.
Results: the symptom scores of cough and expectoration in the observation group were lower after 7 days of treatment; The clinical effective rate (93.33%) was higher than that of the control group (76.67%); IL-4、IgE、TNF－ α The level of serum inflammatory factors in the control group was lower than that in the control group; The adverse reaction rate was only 3.33%, much lower than 13.33% in the control group. There was significant difference between the two groups (P < 0.05).
Conclusion  : loratadine + montelukast sodium can minimize cough sensitivity in children, effectively improve airway hyperresponsiveness, and have excellent effects in relieving cough and asthma and preventing pneumonia. It is worthy of wide application.